Orthofix licenses BoneSource technology to Howmedica
This article was originally published in Clinica
Executive Summary
Orthofix is to license its calcium phosphate-based bone cement, BoneSource, to Pfizer's Howmedica, for the repair of broken bones and filling bone defects. Orthofix, based in Richardson, Texas, will transfer its orthopaedic clinical studies for fracture repair to Howmedica. Howmedica will also carry out worldwide clinical trials into the safety and effectiveness of BoneSource for musculoskeletal procedures.